U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT06928818) titled 'Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea' on March 31.
Brief Summary: Prospective observational study of trastuzumab emtansine immediately after trastuzumab deruxtecan in patients with advanced HER2-positive breast cancer in Korea
Study Start Date: Feb. 26
Study Type: OBSERVATIONAL
Condition:
Cancer of Breast
Trastuzumab Emtansine
Trastuzumab Deruxtecan
Recruitment Status: RECRUITING
Sponsor: Seoul National University Hospital
Information provided by (Responsible Party): Kyung-Hun Lee, Seoul National University Hospital
Published by HT Digital Content Services ...